The Clinical Value of Proposed Risk Stratification Tools in Pediatric Pulmonary Arterial Hypertension

Haarman et al discuss their study on the clinical value of proposed risk stratification tools in pediatric pulmonary arterial hypertension (PAH) which is a rare and lethal disease. Although the availability of PAH-targeted drugs has improved the outcome for these patients, there is still a great need for optimization of treatment strategies. In this context, accurate risk stratification of patients with PAH is regarded as crucial. During the World Symposium on Pulmonary Hypertension in 2013, a pediatric task force proposed a risk stratification tool for children with PAH that stratifies children into a lower-or higher-risk group for mortality.